Supernus Pharma (SUPN) Tops Q2 EPS by 23c

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.43, $0.23 better than the analyst estimate of $0.20. Revenue for the quarter came in at $141.3 million versus the consensus estimate of $134.87 million.

GUIDANCE:

Supernus Pharma sees FY2021 revenue of $550-580 million, versus the consensus of $558 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance